Valiant Laboratories Limited (NSE: VALIANTLAB | BSE: 543998)
Source: Valiant Laboratories Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026)
📋 Quick Facts: Company Snapshot
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Valiant Laboratories Limited |
| Corporate Identity Number (CIN) | L24299MH2021PLC365904 |
| ISIN | INE0OK501015 |
| NSE Symbol & BSE Scrip Code | NSE Symbol: VALIANTLAB | BSE Code: 543998 |
| Date of Incorporation / Founding Year | Originally formed as a partnership firm in 1980 as M/s. Bharat Chemicals; Converted into a public limited company on August 16, 2021 |
| Founders / Key Founding Figures | Mr. Chandrakant V. Gogri (Founder of Aarti Group of Industries) |
| Registered Office & Corporate Headquarters | Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (West), Mumbai – 400080, Maharashtra. Corporate Office: 701-A, 7th Floor, Tower-B, Embassy 247, L.B.S. Road, Vikhroli (West), Mumbai – 400083, Maharashtra. |
| Telephone & Investor Relations Contact | T: 022-49717221 / 49712001 / 49717220 | E: investor@valiantlabs.in |
| Chairman / Managing Director & CEO | Mr. Mulesh Savla (Chairman & Non-Executive Independent Director) | Mr. Santosh Vora (Managing Director) |
| Chief Financial Officer (CFO) & Company Secretary (CS) | Mr. Paresh Shah (Whole-Time Director & Chief Financial Officer) | Mr. Akshay Gangurde (Company Secretary & Compliance Officer) |
| Promoter & Holding Group | Part of the Aarti Group of Industries (Holding Entity: Dhanvallabh Ventures LLP) |
| Industry / Sector Classification | Pharmaceuticals / Active Pharmaceutical Ingredients (APIs) & Specialty Chemicals |
| Total Employees / Permanent & Contractual Workforce | 84 permanent employees on rolls as on March 31, 2026 |
| Manufacturing Plants / Branches / Offices Count | Manufacturing facility at Tarapur Industrial Estate, Palghar, Maharashtra; Wholly-owned subsidiary greenfield facility at Saykha GIDC, Bharuch, Gujarat |
| Countries / States Served | Domestic Indian markets and international export destinations |
| Statutory Auditors | M/s. Raman S. Shah & Co., Chartered Accountants |
| Registrar and Share Transfer Agent (RTA) | MUFG Intime India Pvt. Ltd. (C-101, 247 Park, L.B.S. Road, Vikhroli (West), Mumbai – 400083) |
🏢 The Corporate Identity: Valiant Laboratories Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Valiant Laboratories Limited is a pharmaceutical company and one of India’s leading manufacturers of high-quality Active Pharmaceutical Ingredients (APIs), maintaining a strong specialized focus within the Paracetamol API segment. Backed by over 45 years of manufacturing excellence originating from the Aarti Group legacy, the Company operates an integrated production ecosystem engineered to deliver superior quality products punctually and at competitive prices. Through structured backward integration, technological process innovation, and rigorous quality systems, the Company bridges critical raw material sourcing with scalable pharmaceutical production to serve domestic and international healthcare markets.
The Founders, Promoters & Their Legacy
The enterprise traces its foundational roots back to 1980 with Bharat Chemicals, established by Mr. Chandrakant V. Gogri, the founder of Aarti Industries Limited. Mr. Gogri holds a degree in Chemical Engineering from the Institute of Chemical Technology (ICT) and brought unparalleled expertise in chemical industry projects, operations, process development, and marketing. Operating as an integral part of the Aarti Group, Valiant Laboratories benefits from this enduring legacy, leveraging decades of technical mastery in complex chemistries—such as Para Nitro Phenol production—to drive its pharmaceutical expansion and strategic positioning.
The Journey: Corporate History & Key Milestones
The evolution of the manufacturing and corporate footprint spans several defining milestones across four decades:
- 1980: Established as a partnership firm under the name M/s. Bharat Chemicals, marking the beginning of the manufacturing journey.
- 1982: Commenced the manufacturing of Paracetamol.
- 2004–2005: Expanded the Tarapur presence with the acquisition of plots L-28, L-29, and L-13 (part), taking the total manufacturing footprint to approximately 3,000 square meters.
- 2021: Converted from a partnership firm into a public limited company under the name Valiant Laboratories Limited on August 16, 2021; annual revenue from operations crossed ₹1.00 Crores.
- 2022: Annual revenue from operations crossed ₹0.20 Crores; formed the wholly-owned subsidiary Valiant Advanced Sciences Private Limited (VASPL) to diversify business activities.
- 2023: Successfully completed its Initial Public Offering (IPO) and listed equity shares on BSE and NSE on October 6, 2023.
- 2025: Enhanced Tarapur manufacturing capacity from 9,000 MT to 10,800 MT per annum. Commercialised VASPL’s specialty chemicals greenfield facility at Saykha, Gujarat in November 2025, marking its transition into commercial production of ketene and diketene derivatives. Completed a Rights Issue raising ₹0.81 Crores in August 2025 to fully repay term borrowings.
The Corporate Umbrella & Group Structure
Valiant Laboratories Limited operates as a public listed entity within the Aarti Group. The Company holds 100% equity ownership in its material wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL), which houses the newly commissioned greenfield specialty chemicals manufacturing plant at Saykha, Gujarat. This group structure establishes complete backward integration for the parent company’s core Paracetamol operations, securing key starting materials locally within the corporate network.
⚙️ The Business Engine: Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
The Company is engaged in the manufacture and sale of Active Pharmaceutical Ingredients, principally Paracetamol API. In accordance with Ind AS 108 – Operating Segments, the Chief Operating Decision Maker reviews the business as a single operating segment (Pharmaceuticals). Consequently, separate segment reporting is not applicable.
| Consolidated Revenue Particulars | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Sale of Manufactured Products | 229.29 | 129.72 | +76.76% |
| Sale of Traded Products | 5.17 | 0.66 | +683.33% |
| Other Operating Revenue | 3.00 | 3.00 | 0.00% |
| Total Revenue from Operations | 237.47 | 133.38 | +78.04% |
The Product & Service Catalog (with Operational KPIs & Order Book)
The Company specializes in the production of Paracetamol Active Pharmaceutical Ingredients across diverse pharmacopeial grades and particle specifications tailored to customer finishing needs:
- Pharmacopeial Standards: Paracetamol IP, BP, EP, and USP grades.
- Physical Grades: Crystal, Powder, Fine Powder, and Pulverised grades.
- Packaging Formats: Packed in drums, bags, or customized customer requirements.
- Manufacturing Capacity: Tarapur facility capacity enhanced from 9,000 MT to 10,800 MT per annum during FY 2025-26.
- Subsidiary Production: VASPL commenced commercial production of Acetic Anhydride and specialty chemicals at Saykha, Gujarat in November 2025.
The Names You Know: Key Brands & Flagship Portfolio
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Paracetamol API (IP / BP / EP / USP) | Active Pharmaceutical Ingredient (Analgesic & Antipyretic) | Global and domestic pharmaceutical finished dosage manufacturers for tablets, capsules, and oral liquid formulations. |
| Acetic Anhydride & Specialty Chemicals | Specialty Chemicals (VASPL Subsidiary) | End-use applications in agrochemical, pharmaceutical, dye, pigment, fragrance, food, and polymer industries. |
Mapping the Domestic & Global Reach (India vs. Exports)
The Company maintains a robust domestic distribution footprint across India while expanding its export reach into semi-regulated and international markets supported by ISO 9001:2015 and GMP certifications.
| Geographical Segment Revenue | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Within India (Domestic) | 233.37 | 132.74 | +75.81% |
| Outside India (Exports) | 4.10 | 0.64 | +540.62% |
| Total Revenue from Operations | 237.47 | 133.38 | +78.04% |
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
Operational infrastructure is anchored by key strategic locations designed for optimal logistics efficiency:
- Tarapur Manufacturing Facility: Located at Plots L-13, L-28, L-28(Pt), L-29 & L-30, M.I.D.C., Tarapur, Boisar, District Palghar – 401506, Maharashtra. Strategically situated approximately 150 km from JNPT (Nhava Sheva) Port and 110 km from the Mumbai corporate office.
- Saykha Greenfield Facility (VASPL): Located at Saykha GIDC, Bharuch, Gujarat, housing specialty chemical manufacturing operations with ISO 9001, ISO 14001, and ISO 45001 management systems certifications.
- Corporate Office: 701-A, 7th Floor, Tower-B, Embassy 247, L.B.S. Road, Vikhroli (West), Mumbai – 400083, Maharashtra.
- Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (West), Mumbai – 400080, Maharashtra.
📊 The Financial Health: The Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores / Lakhs Standalone & Consolidated Summary)
| Standalone Financial Parameter | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | Latest YoY (%) |
|---|---|---|---|---|---|
| Revenue from Operations (₹ in Crores) | 237.47 | 133.38 | 182.05 | 333.91 | +78.04% |
| EBITDA (₹ in Crores) | 10.07 | 0.75 | 1.27 | 39.95 | +1242.67% |
| EBITDA Margin (%) | 4.64% | 0.56% | 0.70% | 11.97% | – |
| Profit Before Tax / PBT (₹ in Crores) | 7.55 | (1.45) | (0.75) | 38.14 | N/M |
| Profit After Tax / PAT (₹ in Crores) | 5.55 | (2.15) | 0.34 | 29.00 | N/M |
Earnings, Expenses, & Take-Home Profits (Consolidated Statement of Profit & Loss)
| Consolidated Statement of Profit & Loss | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 237.47 | 133.38 | +78.04% |
| Other Income | 2.32 | 5.43 | -57.27% |
| Total Income | 239.79 | 138.82 | +72.73% |
| Cost of Materials Consumed | 190.80 | 112.18 | +70.08% |
| Purchase of Stock-in-Trade | 9.04 | 0.56 | +1514.29% |
| Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress | (2.68) | 3.86 | N/M |
| Employee Benefits Expense | 7.00 | 4.39 | +59.45% |
| Finance Costs | 1.90 | 0.18 | +955.56% |
| Depreciation, Amortization and Impairment Expenses | 6.04 | 2.09 | +189.00% |
| Other Expenses | 26.92 | 17.07 | +57.70% |
| Total Expenses | 239.02 | 140.33 | +70.33% |
| Profit / (Loss) Before Tax | 0.77 | (1.51) | N/M |
| Tax Expense (Current & Deferred) | 4.04 | 0.69 | +485.51% |
| Profit / (Loss) for the Year | (3.27) | (2.20) | +48.64% |
| Other Comprehensive Income / (Loss) (Net of Tax) | 0.00 | (0.02) | -100.00% |
| Total Comprehensive Income / (Loss) for the Year | (3.26) | (2.23) | +46.19% |
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
| Consolidated Balance Sheet Particulars | As at March 31, 2026 (₹ in Crores) | As at March 31, 2025 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| ASSETS | |||
| Property, Plant and Equipment | 225.79 | 47.88 | +371.57% |
| Right-of-Use Assets | 1.23 | 0.45 | +173.33% |
| Capital Work-in-Progress (CWIP) | 6.08 | 155.78 | -96.10% |
| Other Intangible Assets | 0.11 | 0.11 | 0.00% |
| Other Financial Assets (Non-Current) | 2.41 | 3.57 | -32.49% |
| Other Non-Current Assets | 0.04 | 0.45 | -91.11% |
| Total Non-Current Assets | 235.65 | 208.24 | +13.16% |
| Inventories | 45.43 | 3.99 | +1038.60% |
| Investments (Current) | 26.09 | – | – |
| Trade Receivables | 93.56 | 72.12 | +29.73% |
| Cash and Cash Equivalents | 3.53 | 4.92 | -28.25% |
| Bank Balances Other than Cash & Cash Equivalents | 3.53 | 71.07 | -95.03% |
| Loans (Current) | 0.04 | 0.06 | -33.33% |
| Other Current Assets | 54.46 | 38.26 | +42.34% |
| Current Tax Assets (Net) | 1.68 | 2.19 | -23.29% |
| Total Current Assets | 228.32 | 192.62 | +18.53% |
| TOTAL ASSETS | 463.98 | 400.86 | +15.75% |
| EQUITY AND LIABILITIES | |||
| Equity Share Capital | 54.31 | 43.45 | +24.99% |
| Other Equity | 256.57 | 190.86 | +34.43% |
| Total Equity (Net Worth) | 310.89 | 234.31 | +32.68% |
| Borrowings (Non-Current) | 28.09 | 104.35 | -73.08% |
| Lease Liabilities (Non-Current) | 0.80 | 0.25 | +220.00% |
| Other Non-Financial Liabilities | 0.96 | 0.96 | 0.00% |
| Provisions (Non-Current) | 0.15 | 0.13 | +15.38% |
| Deferred Tax Liabilities (Net) | 3.65 | 1.24 | +194.35% |
| Total Non-Current Liabilities | 33.65 | 106.93 | -68.53% |
| Borrowings (Current) | 16.86 | 16.86 | 0.00% |
| Lease Liabilities (Current) | 0.47 | 0.23 | +104.35% |
| Trade Payables (Micro & Small Enterprises) | 2.93 | 3.79 | -22.69% |
| Trade Payables (Others) | 91.09 | 36.93 | +146.66% |
| Other Financial Liabilities (Current) | 2.26 | 1.35 | +67.41% |
| Other Current Liabilities | 5.53 | 0.26 | +2026.92% |
| Provisions (Current) | 0.32 | 0.20 | +60.00% |
| Total Current Liabilities | 119.45 | 59.62 | +100.35% |
| TOTAL EQUITY AND LIABILITIES | 463.98 | 400.86 | +15.75% |
Cash Flow: Tracking the Money Movement
| Consolidated Statement of Cash Flows | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Net Profit Before Tax | 0.77 | (1.51) | N/M |
| Operating Profit Before Working Capital Changes | 7.66 | 2.78 | +175.54% |
| Cash Generated from Operations | (942.21) | (115.18) | +718.03% |
| Income Tax Paid / Net | (1.01) | 2.47 | N/M |
| Net Cash From / (Used in) Operating Activities (A) | (10.43) | 1.31 | N/M |
| Acquisition of Property, Plant and Equipment and CWIP (Net) / CapEx | 34.20 | 113.85 | -69.96% |
| Sale Proceeds on Property, Plant and Equipment | 0.10% | 1.98% | – |
| Bank Balances Not Considered as Cash and Cash Equivalents | 67.55 | 23.42 | +188.43% |
| Redemption / (Investment) in Mutual Funds (Net) | (26.12) | 37.61 | N/M |
| Net Cash From / (Used in) Investing Activities (B) | 7.25 | (52.77) | N/M |
| Proceeds / (Repayment) from Short-Term Borrowings | 0.10% | 1.98% | – |
| Proceeds / (Repayment) from Long-Term Borrowings | 0.10% | 1.98% | – |
| Proceeds from Share Capital / Rights Issue Premium | 0.10% | 1.98% | – |
| Interest Paid | (1.78) | (0.18) | +888.89% |
| Net Cash From / (Used in) Financing Activities (C) | 1.79 | 44.65 | -95.99% |
| Net Increase / (Decrease) in Cash and Cash Equivalents (A + B + C) | (1.39) | (6.80) | -79.56% |
| Opening Balance of Cash and Cash Equivalents | 4.92 | 11.72 | -58.02% |
| Closing Balance of Cash and Cash Equivalents | 3.53 | 4.92 | -28.25% |
👥 Power & Control: Corporate Governance, Leadership & Ownership
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Mr. Mulesh Manilal Savla | Chairman & Director | 07474847 | Non-Executive Independent Director |
| Mr. Santosh Shantilal Vora | Managing Director | 07633923 | Executive Managing Director |
| Mr. Paresh Shashikant Shah | Whole-Time Director & Chief Financial Officer | 08291953 | Executive Director & CFO |
| Mr. Shantilal Shivji Vora | Director | 07633852 | Non-Executive Director |
| Mr. Sandeep Gupta | Director | 09245060 | Non-Executive Director |
| Mrs. Sonal Amit Vira | Director | 09505883 | Non-Executive Independent Director |
| Mr. Ashok Lakhamshi Chheda | Director | 10776571 | Non-Executive Independent Director |
| Mr. Akshay Gangurde | Company Secretary & Compliance Officer | N.A. (ACS: 70561) | Key Managerial Personnel |
Who Owns the Stock? Shareholding Pattern
The shareholding structure of the Company as on March 31, 2026, reflects strong promoter backing coupled with institutional and retail participation across 5,43,12,500 total equity shares.
| Category of Equity Shareholder | No. of Shares | % of Total Shares |
|---|---|---|
| Promoter and Promoter Group | 4,06,41,487 | 74.83 |
| Resident Individuals | 1,01,22,827 | 18.64 |
| Body Corporate | 16,62,072 | 3.06 |
| Clearing Members | 7,46,383 | 1.37 |
| Hindu Undivided Family (HUF) | 7,99,656 | 1.47 |
| Body Corp – LLP | 1,23,910 | 0.23 |
| Non-Resident Indians (NRIs) | 1,07,366 | 0.20 |
| Foreign Portfolio Investors (FPI) | 1,08,114 | 0.20 |
| Escrow Demat Account | 685 | 0.00 |
| Total | 5,43,12,500 | 100.00 |
🗺️ The Corporate Family Tree: Group Structure & Strategic Investments
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
| Entity Name | Relationship | Country | % Shareholding | Turnover (₹ in Crores) | Profit / (Loss) After Tax (₹ in Crores) |
|---|---|---|---|---|---|
| Valiant Advanced Sciences Private Limited (VASPL) | Wholly Owned Subsidiary | India | 100.00% | 41.65 | (8.82) |
🎯 The Strategic Outlook: Competitive Moats, Risks & Future Growth Plans
Competitive Advantages & Economic Moats
Valiant Laboratories derives its economic moat from its established market leadership in the Paracetamol API segment, backed by over 45 years of manufacturing excellence within the Aarti Group. The Company possesses a strong cost-competitive manufacturing platform at Tarapur, supported by ISO 9001:2015 and GMP certifications. Complete backward integration—anchored by localized sourcing of key starting materials like Para-Aminophenol (PAP) from Aarti Group entities and Acetic Anhydride production at subsidiary VASPL—insulates the business from import volatility and secures supply chain continuity.
What Could Go Wrong? Key Challenges & Business Risks
Principal risk factors confronting the business include raw material price volatility, particularly concerning imported key starting materials and global chemical intermediates. The Company faces competitive pricing pressures within the Paracetamol API market driven by sector-wide capacity additions. Additionally, currency fluctuations, evolving environmental and regulatory compliance standards, and fixed cost absorption risks associated with newly commissioned greenfield capacities represent ongoing operational watchpoints.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
Strategic priorities focus on accelerating the commercial ramp-up and customer validations of specialty chemical products from the newly operational VASPL greenfield facility at Saykha, Gujarat. Management aims to leverage the deleveraged balance sheet—achieved through the ₹0.81 Crores Rights Issue proceeds applied toward term loan repayment—to pursue WHO-GMP compliance, expand regulated and semi-regulated export footprints, and optimize operational efficiencies across all manufacturing assets.
The Verdict: Strategic Outlook & Conclusion
Valiant Laboratories has successfully navigated industry downcycles by strengthening its balance sheet to a debt-free footing, expanding manufacturing throughput, and executing structural backward integration through VASPL. While initial depreciation and tax charges on newly capitalized assets impacted consolidated bottom-line profitability during FY 2025-26, the standalone business returned firmly to profitable operations. With stabilized operations, enhanced capacities, and dedicated focus on high-purity API production, the Company is well-positioned for sustained progress and value creation.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://valiantlabs.in